SXTP 60 Degrees Pharmaceuticals, Inc.
Company Updates ·
All five patients who finished the expanded access study reported improved outcomes and negative conventional PCR tests, and four of five were also negative on a highly sensitive test.
At an October 6, 2026 webinar, the company said 30 patients were enrolled in its hospital study and that it plans to complete the current dataset and move to unblinding.
A September 12, 2026 submission asks FDA for a Commissioner's National Priority Voucher for an efficacy supplement to ARAKODA in babesiosis.
A September 2026 investor presentation lists a $1.0M July 31 private placement, about $1.0M of cash at June 30, 2026, and a runway the slide dates to early October 2026.
60 Degrees sold shares at $1.74 for approximately $1.0 million gross, with H.C. Wainwright & Co. as exclusive placement agent, after its annual report carried a going-concern warning.
A July 2026 corporate presentation says the company targets profitability in 2028, based on malaria prevention sales and a supplemental indication for babesiosis.
60 Degrees Pharmaceuticals priced 2,631,578 shares at $1.90 with warrants. About $5 million comes in up front, and the short-term warrants could bring in about $5 million more only if fully exercised for cash.
60 Degrees Pharmaceuticals sold 1,503,500 shares at $0.715 each in a registered direct offering that closed Feb 6, 2025. H.C. Wainwright was the placement agent, and the company reports about $908,627 of net proceeds, with matching warrants at $0.59.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $1.0 million | $607,574 |
| Research and development | $2.1 million | $5.0 million |
| Net income (loss) | -$7.4 million | -$7.9 million |
| Cash from operations | -$6.8 million | -$5.6 million |
| Cash and equivalents | $1.5 million | $1.7 million |
| Short-term investments | $1.2 million | $1.7 million |
Our latest story on this, dated Aug 4, 2026: "60 Degrees Pharmaceuticals closes private placement for about $1.0 million gross proceeds". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 8, 2026: "60 Degrees presents its July financing and cash runway to investors". The story links the filing or release it is based on. Read the story.
60 Degrees Pharmaceuticals, Inc. trades under the ticker SXTP on NASDAQ.
60 Degrees Pharmaceuticals, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for 60 Degrees Pharmaceuticals, Inc. is 1946563. Its filings are on SEC EDGAR.
3,516,988 shares as of 2026-08-14, per the cover page of its 10-Q filed 2026-08-14.
Our directory records 60 Degrees Pharmaceuticals, Inc. under United States.
Our directory classifies 60 Degrees Pharmaceuticals, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for 60 Degrees Pharmaceuticals, Inc. is US83006G5009.
aibio.space lists 60 Degrees Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$1.0 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
60 Degrees Pharmaceuticals, Inc. reported a net loss of $7.4 million for the fiscal year ended Dec 31, 2025, and used $6.8 million of cash in operations, per its annual report to the SEC.
$2.1 million in the fiscal year ended Dec 31, 2025, per its annual report.
$1.0 million in cash at Jun 30, 2026, per its 10-Q.
Reported a financing. SEC Form 8-K (Items 7.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). Source
Filed a final prospectus for a securities offering. SEC Form S-1. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio